Original Research
Accepted on 10 Oct 2025
Cost-Effectiveness of Iruplinalkib versus Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-small-cell Lung Cancer Patients in China
in Drugs Outcomes Research and Policies
- 133 views